Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. small molecule drug
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads

Refine by
Date

  • This Year
  • Older

Small Molecule Drug Articles & Analysis

82 news found

Ace Therapeutics Releases BBBporter™ Technology Platform to Overcome the Challenges of Brain Drug Delivery

Ace Therapeutics Releases BBBporter™ Technology Platform to Overcome the Challenges of Brain Drug Delivery

Ace Therapeutics, a biotechnology company pioneering novel central nervous system (CNS) delivery solutions, today announced the release of its BBBporter™ technology platform. This innovative platform is specifically designed to overcome the primary challenge in treating brain diseases: the blood-brain barrier (BBB). By leveraging a suite of biomimetic and AI-powered technologies, ...

ByAce Therapeutics


BOC Sciences Returns to Drug Discovery Chemistry 2025, Seeking Broad Partnerships

BOC Sciences Returns to Drug Discovery Chemistry 2025, Seeking Broad Partnerships

BOC Sciences adds to its participation agenda the prestigious Drug Discovery Chemistry 2025 Conference (April 14-17, 2025), which will be a hybrid event taking place in San Diego, CA, and will offer virtual access for worldwide attendees Drug Discovery Chemistry is a heavyweight industry event. It draws thousands of scientists, biotech innovators, and pharmaceutical executives ...

ByBOC Sciences


Protheragen-ING’s AI-Synthesizer Helps to Streamline the Synthesis of Small Molecule Drugs 

Protheragen-ING’s AI-Synthesizer Helps to Streamline the Synthesis of Small Molecule Drugs 

In an era where technological advancements are constantly reshaping the landscape of the pharmaceutical industry, Protheragen-ING has emerged as a frontrunner with its cutting-edge AI-synthesizer for small molecule drug synthesis. This revolutionary platform is transforming traditional drug formulation processes by employing a unique combination of machine learning algorithms, advanced ...

ByProtheragen-ING


Protheragen-ING AI-Pharma’s AI-Powered Drug Discovery and Design Platform—A Paradigm Shift in Drug Development

Protheragen-ING AI-Pharma’s AI-Powered Drug Discovery and Design Platform—A Paradigm Shift in Drug Development

In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding field is Protheragen-ING AI-Pharma, a contract research and development biotechnology company, offering cutting-edge solutions to researchers through its AI-powered drug discovery and design ...

ByProtheragen-ING


CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. Specializing in complex biologic formulations, Biologics & Biosimilars service team of CD Formulation is revolutionizing how drug conjugate products are conceptualized and produced, ...

ByCD Formulation


Ace Therapeutics Accelerates Preclinical GI and Hepatology Research with Disease Model Customization Services

Ace Therapeutics Accelerates Preclinical GI and Hepatology Research with Disease Model Customization Services

Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. Following with the announcement of developing small molecule drug for glaucoma, Ace Therapeutics recently unveiled disease model customization services to accelerate ...

ByAce Therapeutics


Alfa Cytology Launches Full-Scale Preclinical Services for Pancreatic Cancer Research   

Alfa Cytology Launches Full-Scale Preclinical Services for Pancreatic Cancer Research  

Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. Studies found that the incidence rate of PC has been ...

ByAlfa Cytology


Why small molecule development?

Why small molecule development?

Small molecules play a crucial role in modern drug discovery and development. They are typically organic compounds with a low molecular weight that can easily penetrate cell membranes, making them ideal candidates for targeting intracellular pathways and interacting with specific proteins or enzymes. Small molecule drugs have a proven track record of success in treating a wide range of diseases, ...

ByProtheragen-ING


CD Formulation Newly Launches Dissolving Microneedle Preparation Services: Enhancing Drug Delivery Efficiency   

CD Formulation Newly Launches Dissolving Microneedle Preparation Services: Enhancing Drug Delivery Efficiency  

CD Formulation, a leading provider of contract pharmaceutical formulation development services, recently announced the launch of its dissolving microneedle preparation services. This breakthrough in drug delivery technology promises to revolutionize the way medications are administered, enhancing efficiency and patient comfort. Microneedles are tiny, painless needles that penetrate the skin's ...

ByCD Formulation


CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...

ByCD ComputaBio


Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions

Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions

Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...

ByAlfa Chemistry


Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research

Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research

Creative Diagnostics, a global leader in providing raw materials, antibodies, and reagents for the biotechnology industry, recently introduced comprehensive contract ELISA kit development services to the R&D and IVD communities, facilitating regulatory approval submissions. With expertise in antibody generation and immunoassay development, Creative Diagnostics can generate various diagnostic ...

ByCreative Diagnostics


CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service

CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service

CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly ...

ByCD ComputaBio


ViGeneron Announces Closing of Series A Financing to Drive Development of Next Generation Gene Therapy Pipeline

ViGeneron Announces Closing of Series A Financing to Drive Development of Next Generation Gene Therapy Pipeline

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. Funds will advance development of ViGeneron’s next-generation ...

ByViGeneron GmbH


Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired arm’s ...

ByBayer AG


Proteros receives minority investment from private equity firm Inflexion

Proteros receives minority investment from private equity firm Inflexion

Proteros biostructures GmbH, a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding. The transaction is subject to customary regulatory ...

ByProteros Biostructures GmbH


Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, ...

ByContext Therapeutics Inc.


CD Formulation: One-Stop Pharmaceutical Formulation Solution Makes Drug Development Faster, Easier and More Cost-Effective

CD Formulation: One-Stop Pharmaceutical Formulation Solution Makes Drug Development Faster, Easier and More Cost-Effective

Appropriate drug formulation is a prerequisite for successful drug development. CD Formulation, a highly specialized CRO service provider, recently announced its capability of offering one-stop pharmaceutical formulation solutions that can make drug development faster, easier, and more cost-effective. Drug formulation, or pharmaceutical formulation, is a universal challenge faced by biotech ...

ByCD Formulation


Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs

Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs

Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds Tavros Therapeutics, Inc., a precision oncology ...

ByBayer AG


Terray Therapeutics and Calico Enter into a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Age-Related Diseases

Terray Therapeutics and Calico Enter into a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Age-Related Diseases

Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale; and Calico Life Sciences, a biotechnology organization focused on age-related interventions and founded by Alphabet and Arthur D. Levinson, today announced a research collaboration to discover and develop small molecule ...

ByTerray Therapeutics, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT